Advaxis wins European patent case concerning Lovaxin-C vaccine The European Patent Court in Munich.

Current Lm vaccines in development target prostate, breast, other and ovarian cancers. Lately, Advaxis completed a Phase I clinical trial of Lovaxin-C. A Phase II scientific trial is planned for patients with cervical intraepithelial neoplasia . The Lm system also offers applications in the fields of infectious disease and autoimmune disorders. For more info on the ongoing company, please visit: About the Lovaxin-C Vaccine Advaxis’ technology platform uses altered Listeria monocytogenes to provide a tumor-particular antigen fusion proteins. Bioengineered Listeria that are attenuated and secrete Advaxis’ proprietary fusion protein, have the ability to generate a robust immune response, break immune tolerance to cancer tumor and create an unusually solid and effective multi-level therapeutic immune response to existing cancers and other diseases.Based on the Postal Inspection Support, in 2004 more than 9.9 million Americans became identification theft victims, costing the united states roughly $US5 billion. California may be the only declare that requires companies to notify residents when personal data is usually compromised. Senator Dianne Feinstein launched legislation in February to need similar disclosures nationwide. Last October in one of the state’s largest protection breaches, the University of California, Berkeley campus warned 1.4 million Californians that a problem had exposed the names, addresses, Social Security figures and birthdays of people who had participated in a state in-home care program.

African-Americans much more likely to make use of ‘quitlines’ than white smokers African-Americans are consistently more likely than white smokers to use phone help lines to quit smoking, and so are more responsive to mass media text messages promoting the ‘quitline,’ finds a long-term California study.